食管癌和肺癌患者放疗前CD4/CD8比值及总B淋巴细胞预测放射性肺炎的价值

doi:10.3760/cma.j.cn371439-20201209-00101

摘要/Abstract

摘要：

目的探讨食管癌和肺癌患者放疗前CD4/CD8比值及总B淋巴细胞在预测放射性肺炎(RP)发生中的价值。方法回顾性分析2018年4月至2020年3月在中国科学院合肥肿瘤医院接受放疗的28例食管癌和16例肺癌患者的临床病理资料,根据患者治疗期间及治疗后是否发生RP将患者分为RP组(n=16)和非RP组(n=28)。比较两组患者放疗前CD4/CD8比值及总B淋巴细胞、RP组患者放疗前后CD4/CD8比值及总B淋巴细胞,采用受试者工作特征曲线分析放疗前CD4/CD8比值及总B淋巴细胞预测RP的价值。结果 RP组患者放疗前CD4/CD8比值(0.993±0.179)低于非RP组(1.708±0.170),差异有统计学意义(t=2.706,P=0.009);RP组患者血清总B淋巴细胞[(4.409±0.823)%]低于非RP组[(8.153 ±1.017)%],差异有统计学意义(t=0.986,P=0.015)。RP组患者接受胸部放疗后发生RP时CD4/CD8比值(0.785±0.167)较放疗前(0.993±0.179)降低,但差异无统计学意义(t=1.376,P=0.189);RP组患者接受胸部放疗后发生RP时总B淋巴细胞[(3.487±1.018)%]较放疗前[(4.409±0.823)%]降低,但差异无统计学意义(t=0.804,P=0.433)。CD4/CD8比值、总B淋巴细胞预测RP的临界值分别为0.580、0.357。CD4/CD8比值预测RP的曲线下面积(AUC)为0.802(95%CI为0.653~0.932),敏感性为89.29%,特异性为68.75%;总B淋巴细胞预测RP的AUC为0.694(95%CI为0.483~0.814),敏感性为85.71%,特异性为50.00%;两项联合预测RP的AUC为0.834(95%CI为0.697~0.932),敏感性为81.25%,特异性为89.29%;两项联合检测时AUC分别明显高于单独检测,差异均有统计学意义(Z=1.115,P=0.046;Z=1.992,P=0.026)。结论 RP组患者放疗前CD4/CD8比值、总B淋巴细胞低于非RP组患者,血清CD4/CD8比值、总B淋巴细胞在预测接受胸部放疗的恶性肿瘤患者发生RP方面有重要意义。

关键词: 食管肿瘤, 肺肿瘤, CD4/CD8比值, B-淋巴细胞, 危险性评估, 放射性肺炎

Abstract:

Objective To investigate the value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting the occurrence of radiation pneumonitis (RP) in patients with esophageal cancer and lung cancer. Methods The clinicopathological data of 28 patients with esophageal and 16 patients with lung cancer undergoing radiotherapy from April 2018 to March 2020 in Hefei Cancer Hospital, Chinese Academy of Sciences were retrospectively analyzed, and the patients were divided into RP group (n=16) and non-RP group (n=28) according to whether RP occurred during and after treatment. The CD4/CD8 ratio and total B lymphocytes before radiotherapy between the two groups, and the CD4/CD8 ratio and total B lymphocytes before and after radiotherapy in the RP group were compared. Receiver operating characteristic curve was used to analyze the value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting RP. Results The CD4/CD8 ratio before radiotherapy in the RP group was significantly lower than that in the non-RP group (0.993±0.179 vs. 1.708±0.170), with a statistically significant difference (t=2.706, P=0.009); the total B lymphocytes in the RP group was significantly lower than that in non-RP group [(4.409±0.823)% vs. (8.153±1.017)%], with a statistically significant difference (t=0.986, P=0.015). The CD4/CD8 ratio in the RP group was lower than that before radiotherapy when RP occurred (0.785±0.167 vs. 0.993±0.179), with no statistically significant difference (t=1.376, P=0.189). The total B lymphocytes in the RP group was lower than that before radiotherapy when RP occurred [(3.487±1.018)% vs. (4.409±0.823)%], with no statistically significant difference (t=0.804, P=0.433). The critical values of CD4/CD8 ratio and total B lymphocytes predicted RP were 0.580 and 0.357, respectively. The areas under the curve (AUC) of CD4/CD8 for predicting RP was 0.802 (95%CI: 0.653-0.932), the sensitivity was 89.29%, and the specificity was 68.75%. The AUC of total B lymphocytes for predicting RP was 0.694 (95%CI: 0.483-0.814), the sensitivity was 85.71%, and the specificity was 50.00%. The AUC of the two combined diagnostic method for RP was 0.834 (95%CI: 0.697-0.932), the sensitivity and specificity were 81.25% and 89.29%. AUC of the two combined tests was significantly higher than that of the single test, with statistically significant differences (Z=1.115, P=0.046; Z=1.992, P=0.026). Conclusion The CD4/CD8 ratio and total B lymphocytes in the RP group are lower than those in the non-RP group. The CD4/CD8 ratio and total B lymphocytes in the serum are of great significance in predicting the occurrence of RP in patients with malignant tumors receiving chest radiotherapy.

Key words: Esophageal neoplasms, Lung neoplasms, CD4/CD8 ratio, B-lymphocytes, Risk assessment, Radiation pneumonitis

胡格, 苏杰, 李蔷薇, 徐鹏, 徐秀理, 钱晓涛. 食管癌和肺癌患者放疗前CD4/CD8比值及总B淋巴细胞预测放射性肺炎的价值[J]. 国际肿瘤学杂志, 2021, 48(9): 523-526.

Hu Ge, Su Jie, Li Qiangwei, Xu Peng, Xu Xiuli, Qian Xiaotao. Value of CD4/CD8 ratio and total B lymphocytes before radiotherapy in predicting radiation pneumonitis in patients with esophageal cancer and lung cancer[J]. Journal of International Oncology, 2021, 48(9): 523-526.

图/表 2

参考文献 12

[1]	国家卫生和计划生育委员会统计信息中心, 中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国死因监测数据集2016[M]. 北京: 中国科学技术出版社, 2017: 26.
[2]	陈万青, 李贺. 人群肿瘤监测在癌症防控中的作用[J]. 肿瘤预防与治疗, 2018, 31(1):1-4. DOI: 10.3969/j.issn.1674-0904.2018.01.001. doi: 10.3969/j.issn.1674-0904.2018.01.001
[3]	史志勇, 王娟, 苏铁涛, 等. 肺癌患者发生放射性肺损伤的相关因素[J]. 临床与病理杂志, 2018, 38(7):1451-1456. DOI: 10.3978/j.issn.2095-6959.2018.07.013. doi: 10.3978/j.issn.2095-6959.2018.07.013
[4]	乔红梅, 郑安婕, 宁鹏, 等. 放射性肺炎相关细胞因子预测因素的研究进展[J]. 现代肿瘤医学, 2020, 28(15):2730-2734. DOI: 10.3969/j.issn.1672-4992.2020.15.041. doi: 10.3969/j.issn.1672-4992.2020.15.041
[5]	常晓龙, 文景丽, 郭英华, 等. 食管癌和肺癌患者血清IL-10、MMP-9、TNF-α预测放射性肺炎临床观察[J]. 潍坊医学院学报, 2019, 41(4):283-287. DOI: 10.16846/j.issn.1004-3101.2019.04.013. doi: 10.16846/j.issn.1004-3101.2019.04.013
[6]	Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5):1341-1346. DOI: 10.1016/0360-3016(95)00060-C. doi: 10.1016/0360-3016(95)00060-C
[7]	徐金明, 王丽. 肺癌放疗患者放射性肺炎发生情况及影响因素探讨[J]. 临床医药文献电子杂志, 2019, 6(64):58. DOI: 10.16281/j.cnki.jocml.2019.64.046. doi: 10.16281/j.cnki.jocml.2019.64.046
[8]	王树斌, 袁飞, 武云, 等. 放射性肺炎与肺癌患者生物学因素关系的研究进展[J]. 癌症进展, 2018, 16(13):1571-1574. DOI: 10.11877/j.issn.1672-1535.2018.16.13.02. doi: 10.11877/j.issn.1672-1535.2018.16.13.02
[9]	Hu Z, Lin D, Yuan J, et al. Over expression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer[J]. Clin Cancer Res, 2005, 11(13):4646-4652. DOI: 10.1158/1078-0432.CCR-04-2013. doi: 10.1158/1078-0432.CCR-04-2013
[10]	叶萍. 肿瘤患者外周血T淋巴细胞亚群的变化及临床价值分析[J]. 现代诊断与治疗, 2019, 30(22):4005-4007.
[11]	Sheng SY, Gu Y, Lu CG, et al. The distribution and function of human memory T cell subsets in lung cancer[J]. Immunol Res, 2017, 65(3):639-650. DOI: 10.1007/s12026-016-8882-y. doi: 10.1007/s12026-016-8882-y pmid: 28101811
[12]	章梁君, 钟锦莎, 钟辉秀, 等. 恶性肿瘤患者外周血淋巴细胞免疫表型检测的临床意义[J]. 国际检验医学杂志, 2015, 36(24):3565-3567. DOI: 10.3969/j.issn.1673-4130.2015.24.024. doi: 10.3969/j.issn.1673-4130.2015.24.024

一般临床特征	RP组 (n=16)	非RP组 (n=28)	χ²值	P值
性别
男	15	21	1.311	0.252
女	1	7
年龄(岁)
≥60	14	24	0.027	0.768
<60	2	4
病种
食管癌	9	19	0.592	0.441
肺癌	7	9
分期
Ⅰ~Ⅱ	5	11	0.284	0.594
Ⅲ~Ⅳ	11	17
放疗剂量(Gy)
<60	4	8	0.065	0.698
≥60	12	20
同步化疗
有	3	4	0.151	0.627
无	13	24
吸烟史
有	10	17	0.013	0.907
无	6	11

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[6]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[9]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[10]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[11]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[12]	曹晓辉, 于荭, 李万湖. 基于CT的影像组学分析在预测和鉴别治疗相关性肺炎中的应用[J]. 国际肿瘤学杂志, 2023, 50(2): 107-111.
[13]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[14]	左小平, 刘晓川, 吴西强, 李周, 夏天, 刘国凤. 老年早期肺癌患者经胸腔镜肺切除术后心律失常发生的危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(12): 711-716.
[15]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.